Genomic Prediction

Executive Summary

Genomic Prediction, operating as LifeView, is a US-based biotechnology company specializing in advanced preimplantation genetic testing (PGT) for in vitro fertilization (IVF). The company offers a comprehensive suite of tests including chromosomal aneuploidy screening, single-gene disorder detection, and polygenic risk assessment through its flagship Embryo Health Score, which evaluates an embryo's genetic predisposition to complex diseases. By integrating these tests, Genomic Prediction aims to improve IVF success rates, reduce miscarriage risk, and provide prospective parents with deeper genetic insights. Founded in 2017 and headquartered in San Francisco, the company is positioned at the intersection of reproductive technology and genomic medicine, targeting a rapidly growing global IVF market. Despite its innovative approach, Genomic Prediction faces regulatory and ethical challenges, particularly around polygenic embryo selection, which could limit adoption. The company's success hinges on clinical validation of its Embryo Health Score, navigating FDA oversight for laboratory-developed tests, and forging partnerships with major fertility clinics. The addressable market is substantial, driven by increasing IVF utilization and demand for genetic screening. Overall, the company presents a high-risk, high-reward opportunity, with potential for significant impact if clinical and regulatory hurdles are overcome.

Upcoming Catalysts (preview)

• 2026Publication of clinical validation data for Embryo Health Score in a peer-reviewed journal70% success
• 2026FDA clearance or LDT guidance clarification for polygenic risk scores in PGT50% success
• 2026Strategic partnership with a leading fertility clinic network for exclusive test adoption60% success